HEALTH PROFESSIONAL · SOURCE READING

Lenalidomide and rituximab

Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.

Context: Treatment of Indolent, Recurrent B-Cell Non-Hodgkin Lymphoma / Treatment Options for Indolent, Recurrent B-Cell NHL

Responses of 20% to 56% have been reported for lenalidomide, especially in patients with follicular lymphoma and small lymphocytic lymphoma, with even higher responses noted for the combination of lenalidomide and rituximab.[21,22][Level of evidence C3]

Source links and citations

21
22
Level of evidence C3

Publication references

Read the original reference and check its publication notices.

PubMed 19805688 · Original source
PubMed 26304886 · Original source

Preserved source evidence · Independent clinical review pending · Not medical advice